ISOQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION, COMPRISING SAME AS ACTIVE INGREDIENT, FOR PREVENTION OR TREATMENT OF POLY(ADP-RIBOSE)POLYMERASE-1 (PARP-1)-ASSOCIATED DISEASE
申请人:Digmbio. Inc.
公开号:EP4053106A1
公开(公告)日:2022-09-07
The present invention relates to isoquinolinone derivatives, a method for preparing the same, and a pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1 (PARP-1)-related diseases containing the same as an active ingredient. The isoquinolinone derivatives exhibit an excellent PARP-1 inhibitory effect at a concentration of nanomolar units, and further exhibit an excellent cytoprotective effect (apoptosis inhibitory effect) on ophthalmic diseases or disorders, specifically retinal disorders, and thus can be effectively used as a pharmaceutical composition for preventing or treating PARP-1-related diseases, for example, ophthalmic diseases or disorders, which contains the same as an active ingredient.
本发明涉及异喹啉酮衍生物、其制备方法以及用于预防或治疗与聚(ADP-核糖)聚合酶-1(PARP-1)有关的疾病的药物组合物,其中该异喹啉酮衍生物在纳摩尔单位浓度下表现出优异的PARP-1抑制作用,并在眼科疾病或障碍,特别是视网膜疾病方面表现出优异的细胞保护作用(凋亡抑制作用),因此可以有效地用作预防或治疗PARP-1相关疾病(例如眼科疾病或障碍)的药物组合物的活性成分。